Many of the current immunotherapy studies investigating SCLC mostly use PD-L1 drugs, such as Atezolizumab, as immunological agents; however, we found that the MPR results in the tislelizumab group were not lower than the results of MPR in the Atezolizumab group, and there was a significant economic advantage. Here, CD274 is linked to small cell lung carcinoma.